pubs.acs.org/joc

Article

Ruthenium-Catalyzed Oxidative Cross-Coupling Reaction of Activated Olefins with Vinyl Boronates for the Synthesis of (*E*,*E*)-1,3-Dienes

Dattatraya H. Dethe,* Nagabhushana C. Beeralingappa, and Amar Uike



activated olefins and vinyl boronate derivatives has been developed for the highly stereoselective construction of synthetically useful (E,E)-1,3-dienes. The highlight of this reaction is that exclusive stereoselectivity (only *E,E*-isomer) was achieved from a base-free, ligand-free, and mild catalytic condition with a less expensive $[RuCl_2(p-cymene)]_2$ catalyst.



■ INTRODUCTION

Palladium-catalyzed arylation of olefins has been routinely used as powerful carbon-carbon bond forming reactions (Scheme 11:a) since its discovery in the early 1970s, which triggered the era of natural product synthesis and medicinal chemistry.¹⁻⁶ Substituted 1,3-dienes are valuable synthetic intermediates in organic chemistry, which also feature as structural motifs in numerous natural products and medicinally important molecules.' Indeed, these conjugated dienes serve as building blocks for fabricating the complexity in chemical transformations such as cross-coupling reactions, cycloadditions, ene-reaction, and metathesis, including recently developed asymmetric hydrofunctionalizations, difunctionalizations, etc. It is well-understood that the syntheses of stereo- and regiodefined conjugated dienes are often influenced by the geometry of olefins involved in the reaction.⁸ Hence, innumerable synthetic strategies have been explored for the stereoselective construction of substituted 1,3-dienes.9 Oxidative boron Heck reactions are known to be efficient, require mild reaction conditions, show good functional group tolerance, and are capable of coupling challenging substrates such as highly substituted or cyclic olefins, many of which are reluctant to undergo normal Heck coupling.¹⁰ In this regard, many oxidative Heck reactions of phenyl boronates with activated olefins have been developed,¹¹⁻¹⁴ but there is only one report in the literature on oxidative Heck reaction using alkenyl boranes by Jung et al. (Scheme 11:b).¹⁵ Although this protocol developed by Jung et al. provides access to dienes in very good yields, it gives poor stereoselectivity when acrylonitrile and styrenes are used as coupling partners. The major problem in oxidative Heck coupling is that poor stereoselectivity was observed for these reactions. To overcome these stereoselective problems, sterically hindered acrylates (activated olefins) such as tertiary butyl acrylate were used. This limits the substrate scope and its application in

synthesis. Poor stereoselectivity of the oxidative Heck reaction coupled with skyrocketing prices of palladium has led to an increased need to develop more sustainable strategies for such kinds of carbon–carbon-bond formations. Herein, we report a new catalytic system for the cross-coupling reaction of organoboron compounds with activated olefins to afford conjugated 1,3-dienes in a highly stereoselective manner using the commercially available, less expensive $[RuCl_2(p$ $cymene)]_2$ catalyst and $Cu(OAc)_2$ as a reoxidant for the ruthenium(0) species under base- and ligand-free conditions (Scheme 22:).

RESULTS AND DISCUSSION

An optimization study revealed that the couplings of organoborane derivatives with various acrylates were found to be beneficial in terms of functional group tolerance and yield. To begin with, the cross-coupling reaction was performed using *trans*-2-phenyl vinyl boronic ester **1a** and methyl acrylate **2a** in trifluoroethanol at 80 °C for 12 h with 5 mol % [RuCl₂(*p*-cymene)]₂ as the catalyst, 2 equivalents of Cu(OAc)₂ as the oxidant, and 15 mol % AgSbF₆ as an additive. The desired 1,3-diene **3aa** was obtained in 28% yield as a single *E*,*E*-isomer (Table 1, entry 1). Change of the solvent to CH₃CN, t-AmOH, or NMP (entries 2–4) did not produce better results. Change of the solvent to dichloromethane afforded the coupling product in 35% at 40 °C (entry 5), whereas replacement with toluene generated the cross-coupled

Received: November 26, 2020 Published: February 4, 2021





pubs.acs.org/joc

Article

Scheme 1



Table 1. Optimization of Reaction Conditions

	$B(OR)_{2} + 1a$ $R = H \text{ or } B(OR)_{2} = BO$	OMe [RuCl ₂ (p-cyn additive OMe oxidar 2a solvent	nene)] ₂ (5 mol%) (a (15 mol%) (t (2 equiv) 80 °C, 12 h 3aa	O OMe
entry	solvent	additive (15 mol %)	oxidant (2 equiv)	^e yield [%]
1	TFE	AgSbF ₆	Cu(OAc) ₂ ·H ₂ O	28
2	CH ₃ CN	AgSbF ₆	$Cu(OAc)_2 \cdot H_2O$	trace
3	t-AmOH	AgSbF ₆	$Cu(OAc)_2 \cdot H_2O$	16
4	NMP	AgSbF ₆	$Cu(OAc)_2 \cdot H_2O$	25
5	DCM	AgSbF ₆	$Cu(OAc)_2 \cdot H_2O$	35
6	toluene	AgSbF ₆	$Cu(OAc)_2 \cdot H_2O$	65
7 ^a	toluene	AgSbF ₆	$Cu(OAc)_2 \cdot H_2O$	42
8 ^b	DCE	AgSbF ₆	$Cu(OAc)_2 \cdot H_2O$	45
9	DCE	AgSbF ₆	$Cu(OAc)_2 \cdot H_2O$	88
10	DCE	AgSbF ₆	KOAc	12
11	DCE	NH ₄ PF ₆	Cu(OAc) ₂ ·H ₂ O	75
12	toluene	NH ₄ PF ₆	$Cu(OAc)_2 \cdot H_2O$	48
13	DCE	AgOAc	$Cu(OAc)_2 \cdot H_2O$	trace
14	DCE	Ag ₂ CO ₃	$Cu(OAc)_2 \cdot H_2O$	0
15	DCE		AgOAc	16
16 ^c	DCE		$Cu(OAc)_2 \cdot H_2O$	0
17 ^d	DCE	AgSbF ₆		0

"Reaction Conditions. Reaction at 110 °C. "Reaction at 60 °C. "The reaction was performed without AgSbF₆." The reaction was performed without Cu(OAc)2·H2O. eIsolated yield of 3aa.

product in 65% yield at 80 °C (entry 6). An increase in the temperature to 110 °C resulted in a lower yield probably due to decomposition of the starting material (entry 7). Use of 1,2dichloroethane as a solvent afforded 45% of the desired product at 60 °C (entry 8), and to our delight, when the temperature was increased to 80 °C, the yield increased to 88% (entry 9). When the reaction was conducted by replacing AgSbF₆ with a variety of additives, the reaction was found to be sluggish, but in the case of NH₄PF₆, diene 3 was obtained in 75% yield at 80 °C using 1,2-dichloroethane as a solvent (entry 11). Change of the solvent to toluene and using NH_4PF_6 as an additive at 80 °C afforded the desired coupling product in only 48% yield (entry 12). It was found that similar reactivity in terms of rate and yield was observed when boronate esters

were replaced with corresponding boronic acids. It is noteworthy to mention that the reaction did not occur when carried out in the absence of either $AgSbF_6$ (entry 16) or $Cu(OAc)_2$ (entry 17), revealing that $Cu(OAc)_2$ as a reoxidant and AgSbF₆ as an additive were necessary for the reaction.

The scopes of the alkenyl boronates and the acrylates were subsequently examined. As shown in Scheme 3, phenyl and (4'-methyl) phenyl-substituted vinyl boronates 1a,b reacted well with methyl (2a), butyl (2b), and cyclohexyl (2c) acrylates independently to afford the corresponding crosscoupled products 3aa-bc in very good yields and excellent stereoselectivity. Notably, halogen-containing vinyl boronate derivatives such as 1c-e showed their chemoselective reactivity for the coupling reaction under a reactive catalytic

pubs.acs.org/joc

Article

Scheme 3. Reaction of Various Acrylates with Different Organoboron Derivatives^a



^aReaction conditions: 1 (1 equiv), 2 (1 equiv), $[Ru(p-cymene)Cl_2]_2$ (5 mol %), $AgSbF_6$ (15 mol %), and $Cu(OAc)_2 H_2O$ (2 equiv) at 80 °C in 1,2-DCE (3.0 mL), under argon for 12 h. Cy, cyclohexyl.

system to generate corresponding coupling products 3cb-eb without affecting the labile carbon-halogen (C-Br) bond, which can be utilized for further functionalization. Phenylboronic acid 1f on reaction with various acrylates 2b-egenerated the corresponding cross-coupled products 3fb-fe in very good yields and excellent stereoselectivity. Sterically crowded cyclohexenyl boronate ester 1g reacted smoothly with various acrylates 2a-c, f to generate corresponding dienes 3ga-gc, gf, respectively, in very good yields. Cyclopentenyl boronate ester 1h underwent a coupling reaction with methyl acrylate 2a to afford 3ha in 80% yield. Allyl boronate ester 1i underwent a coupling reaction with methyl (2a) and cyclohexyl acrylate (2c) individually to afford 3ia and 3ic in 70% and 73% yields, respectively. Vinyl boronate ester 1j on reaction with *n*-butyl acrylate (2b) generated the single isomer 3jb in 75% yield. Interestingly, cyclopropyl vinyl boronate ester 1k furnished dienes 3kb and 3kc in 78 and 75% yields, respectively, without affecting its highly strained cyclopropyl ring. It is important to highlight that the coupling reaction of highly strained cyclopropane ring derivatives is likely to undergo ring cleavage under a palladium catalytic system.¹⁶ Also, electron-withdrawing acetoxy-substituted vinyl boronate ester 11 reacted with n-butyl acrylate (2b) to generate functionalized diene 3lb in 82% yield. Highly activated vinyl boronate derivative 1m underwent a coupling reaction with cyclohexyl acrylate (2c) to afford the coupled product 3mc in 84% yield. Interestingly, the introduction of an ester side chain has no effect on product selectivity. Markedly, symmetric diacrylate 2g reacted with vinyl boronate derivative 1m to form the coupled product 3mg in a somewhat moderate yield (68%). Also, these conjugate diesters (3mc, mg) represent the structure of an important class, called muconate derivatives.¹⁷ This differentiable terminal functionality of conjugated muconates can be eventually transformed into versatile synthetic intermediates widely used in organic synthesis. To date, no catalytic method has been developed for the stereoselective construction of (E,E)-muconate derivatives.¹⁸ It is noteworthy to mention that when the coupling reaction

pubs.acs.org/joc

Article





Scheme 5. : Reaction of Organoboron Derivatives with Enones Using NH₄PF₆



was carried out on a gram scale, similar results were obtained without affecting productivity in terms of yield and stereoselectivity.

Moreover, this newly developed catalytic protocol is not limited only to acrylates but also applicable to various activated olefins such as acrylonitrile, vinyl ketones, vinyl sulfones, and acrylamides (Scheme 4). Series of vinyl boronates (1b-d, 1f,g, and 1m) were independently treated with acrylonitrile (4a) to afford the desired products (Sba-da, Sfa, Sga, and Sma) in good yields with excellent stereoselectivity. It is worth mentioning that palladium-catalyzed Heck oxidative coupling showed poor stereoselectivity especially with acrylonitriles.^{15,19} It was interesting to observe that when ethyl vinyl ketone, 4b, was used as a coupling partner, it generated 1,3-dienes embedded with an enone substituent in very good yields. Furthermore, phenyl vinyl sulfone, 4c, was subjected to a coupling reaction to deliver a single (E,E)-isomer of desired dienes 5nc and 5hc in 76 and 70% yields, respectively. A similar reactivity was observed when acrylamide, 4d, was reacted with phenylboronic acid and cyclopentenyl boronate ester to provide corresponding coupling products 5fd and 5hd in 81 and 79% yields, respectively. Additionally, the desired product (5ae) was obtained when (E)-methyl crotonate 4e was subjected to a coupling reaction with boronate ester, albeit with a moderate yield (65%), highlighting the broad scope of an olefinic partner.

Interesting results were observed when coupling reactions between vinyl boronates and α , β -unsaturated ketones were carried out by replacing AgSbF₆ with NH₄PF₆ (Scheme 5). An unanticipated double-bond reduced product, **6ab**, was formed

pubs.acs.org/joc

Article

Scheme 6. Competitive Experiments



Scheme 7. Plausible Mechanism



in 70% yield when boronate ester 1a was reacted with ethyl vinyl ketone 4b. This may be due to facile enol formation/ protonation in the case of enones in the presence of the $\rm NH_4^+$ ion, which restricts β -hydride elimination. To check the generality of this reaction, various vinyl boronate esters were subjected to a coupling reaction with ethyl/methyl vinyl ketone; similar results were obtained and afforded coupling products (6bb, ff, hb, nf) in moderate to good yields.

To determine the effect of substituents on the rate of the coupling reaction, we performed intermolecular competitive reactions between differently substituted vinyl boronates. When (4-methyl)-phenyl (1b) and (4-fluoro)-phenyl (1c) vinyl boronate and methyl acrylate were employed, the electron-rich substrate reacted more predominantly with a reactivity difference of almost 1:0.4 (Scheme 6a). Similarly, a mixture of compounds **3ba** and **3ca** in a 1:0.65 ratio was observed from parallel reactions (Scheme 6b). When a competitive reaction between alkyl and phenyl-substituted vinyl boronate esters was performed, phenyl-substituted vinyl boronate reacted preferentially with a reactivity difference of 1:0.45 (Scheme 6c).

Based on a previous report,²⁰ a plausible reaction mechanism for the cross-coupling reaction of vinyl boronate with activated olefins is depicted in Scheme 7. The catalytic cycle is initiated by in situ-generated reactive ruthenium(II) species A, which further undergoes transmetalation with vinyl boronate ester B to provide an intermediate C. Coordination followed by regioselective insertion of activated olefin to the ruthenium-carbon bond of intermediate C would generate the ruthenium(II) intermediate E. Subsequent β -hydride elimination of E leads to the formation of the stereoselective crosscoupled product P, followed by reductive elimination of the Ru(II) intermediate F, which results in the formation of the Ru(0) intermediate G. In the presence of $Cu(OAc)_2$, the reduced [Ru(0)] species could undergo oxidation to regenerate the ruthenium (II) cationic reactive complex A for the next catalytic cycle. In the presence of NH_4PF_6 , the catalytic cycle follows path B to afford product Q. This unanticipated result may be due to facile enol formation/ protonation in the case of enones in the presence of the NH_4^+ ion, which restricts β -hydride elimination.

CONCLUSIONS

In summary, ruthenium-catalyzed oxidative cross-coupling between vinyl boronates and activated olefins has been developed for efficient and direct access to synthetically useful (E,E)-1,3-dienes in a highly stereoselective manner. This reaction features a base-free, mild reaction condition, easily accessible starting materials, a broad substrate scope, and excellent stereoselectivity. The present simplified methodology for carbon–carbon bond formation is highly practical, holding great promise for wide use in organic and medicinal chemistry.

EXPERIMENTAL SECTION

General Aspects. Experiments involving moisture- and airsensitive components were performed in oven-dried glassware. Commercial solvents and reagents were used without further purification unless otherwise noted. Yields refer to chromatographically pure compounds, unless otherwise stated. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25 mm Merck silica gel plates (60F-254) using UV light as a visualizing agent and *p*-anisaldehyde and heat as developing agents. Merck silica gel (particle size 100–200 and 230–400 mesh) was used pubs.acs.org/joc

for flash column chromatography. Neat compounds were used to record IR spectra. NMR spectra were recorded on a Bruker Avance 400 (1H, 400 MHz; 13C, 100 MHz), Bruker Avance 500 (1H, 500 MHz; 13C, 125 MHz), or JEOL DELTA (ECX) 500 (1H, 500 MHz; 13C, 125 MHz). Mass spectrometric data were obtained using WATERS-Q-Tof-Premier-HAB213 and WATERS-QTof-Premier-ESI-MS instruments, and IR data were recorded from a PerkinElmer FTIR spectrometer. The following abbreviations were used to explain the multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; spt, septet; dd, doublet of doublet; ddd, doublet of a doublet; dt, doublet of a triplet; td, triplet of a doublet; m, multiplet; br, broad.

General Procedure for Ruthenium-Catalyzed Oxidative Coupling Reaction between Activated Olefins and Vinyl Boronate Esters. An 8 mL screw-cap vial was charged with $[RuCl_2(p-cymene)]_2$ (15.5 mg, 0.025 mmol, 5.0 mol %), $Cu(OAc)_2$. H₂O (200 mg, 1.0 mmol, 2.0 equiv), AgSbF₆ (25.7 mg, 0.075 mmol, 15 mol %), and 1,2-dichloroethane (3.0 mL). Then, boronic ester (0.5 mmol, 1.0 equiv) and activated olefins (0.5 mmol, 1.0 equiv) [2.0 equivalents of acrylonitrile and methyl crotonate were used] were added into the solution in sequence. The vial was sealed under N2 and heated to 80 °C with stirring for 12 h (using an oil bath). After cooling down, the mixture was diluted with ethyl acetate, filtered, and concentrated to give the crude compound, which was directly purified by column chromatography. [Note: A general procedure was followed for the oxidative coupling reaction of boronic esters with vinyl ketone in the presence of 30 mol % NH₄PF₆ (25 mg) in the place of AgSbF₆.]

Gram-Scale Synthesis of 3ac. A 100 mL screw-cap vial was charged with $[RuCl_2(p\text{-cymene})]_2$ (134 mg, 0.22 mmol, 5.0 mol %), AgSbF₆ (180 mg, 0.52 mmol, 12 mol %), and Cu(OAc)₂·H₂O (1.8 g, 8.72 mmol, 2.0 equiv) in 1,2-dichloroethane (25 mL) and stirred for 5 minutes at room temperature under a nitrogen atmosphere. Then, phenyl-substituted vinyl boronate ester **1a** (1.0 g, 4.4 mmol, 1.0 equiv) and cyclohexyl acrylate **2c** (0.7 mL, 4.4 mmol, 1.0 equiv, density = 0.975 g/mL) were added into the solution in sequence and the vial was sealed under N₂ and heated to 80 °C with stirring for 12 h (using an oil bath). After cooling down, the mixture was diluted with ethyl acetate, filtered, and concentrated to give the crude compound, which was directly purified by column chromatography to obtain the pure product **3ac** (0.95 g, 3.7 mmol, 85%).

Competitive Reactions between 1b and 1c. An 8 mL screwcap vial was charged with $[\operatorname{RuCl}_2(p\text{-cymene})]_2$ (13 mg, 0.02 mmol, 5.0 mol %), $\operatorname{Cu}(\operatorname{OAc})_2$ ·H₂O (160 mg, 0.8 mmol, 2.0 equiv), AgSbF₆ (21 mg, 0.06 mmol, 15 mol %), and 1,2-dichloroethane (2.5 mL). Then, boronic esters **1b** (50 mg, 0.2 mmol, 0.5 equiv) and **1c** (50 mg, 0.2 mmol, 0.5 equiv) followed by methyl acrylate (38 mg, 0.44 mmol, 1.1 equiv) were added into the solution in sequence. The vial was sealed under N₂ and heated to 80 °C with stirring for 4 h (using an oil bath). After cooling down, the mixture was diluted with ethyl acetate, filtered, and concentrated to give the crude compound, which was directly purified by column chromatography using 0–5% EtOAc in pet ether to afford a mixture of compounds **3ba** and **3ca** in a 1:0.4 ratio.

Parallel Reactions. Similarly, two parallel reactions were performed with 0.2 mmol each of **1b** and **1c** for 4 h at 80 °C. After cooling down, the reaction mixtures were mixed, diluted with ethyl acetate, filtered, and concentrated to give the crude compound, which was directly purified by column chromatography using 0-5% EtOAc in pet ether to afford a mixture of compounds **3ba** and **3ca** in a 1:0.65 ratio.

Competitive Reactions between 1a and 1k. An 8 mL screwcap vial was charged with $[RuCl_2(p-cymene)]_2$ (13 mg, 0.02 mmol, 5.0 mol %), $Cu(OAc)_2$ ·H₂O (160 mg, 0.8 mmol, 2.0 equiv), AgSbF₆ (21 mg, 0.06 mmol, 15 mol %), and 1,2-dichloroethane (2.5 mL). Then, boronic esters **1a** (55 mg, 0.24 mmol, 0.5 equiv) and **1k** (43 mg, 0.24 mmol, 0.5 equiv) followed by methyl acrylate (38 mg, 0.44 mmol, 1.1 equiv) were added into the solution in sequence. The vial was sealed under N₂ and heated to 80 °C with stirring for 4 h (using an oil bath). After cooling down, the mixture was diluted with ethyl acetate, filtered, and concentrated to give the crude compound, which

was directly purified by column chromatography using 0-5% EtOAc in pet ether to afford a mixture of compounds **3aa** and **3ka** in a 1:0.45 ratio.

(2*E*,4*E*)-Methyl 5-Phenylpenta-2,4-dienoate (3aa). Following the general procedure, 3aa was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a white solid (77 mg, 88%). ¹H NMR (500 MHz, CDCl₃) δ 7.49–7.42 (m, 3H), 7.38–7.28 (m, 3H), 6.93–6.83 (m, 2H), 5.99 (d, *J* = 15.3 Hz, 1H), 3.77 (s, 3H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 167.6, 144.9, 140.7, 136.1, 129.2, 128.9 (2C), 127.3 (2C), 126.3, 120.9, 51.7. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₂H₁₃O₂ 189.0916; found 189.0910. IR (neat): v_{max}/cm^{-1} 2926, 1717, 1628, 1439, 1450, 1321, 1344, 1242, 1172, 1137, 995.

(2*E*,4*E*)-Methyl 5-*p*-Tolylpenta-2,4-dienoate (3ba). Following the general procedure, 3ba was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a white solid (81 mg, 86%). ¹H NMR (400 MHz, CDCl₃) δ 7.44 (dd, *J* = 9.8, 15.3 Hz, 1H), 7.37–7.33 (m, 2H), 7.17–7.13 (m, 2H), 6.90–6.77 (m, 2H), 5.96 (d, *J* = 15.3 Hz, 1H), 3.76 (s, 3H), 2.35 (s, 3H). ¹³C NMR{¹H} (100 MHz, CDCl₃) δ 167.6, 145.1, 140.7, 139.4, 133.4, 129.6(2C), 127.2(2C), 125.3, 120.3, 51.6, 21.4. HRMS (ESI-TOF) *m/z*: $[M + H]^+$ calcd for C₁₃H₁₅O₂ 203.1072; found 203.1070. IR (neat): *v*_{max}/cm⁻¹ 2924, 1711, 1605, 1622, 1434, 1350, 1318, 1243, 1171, 1132, 1010, 840, 806.

(2*E*,4*E*)-Butyl 5-Phenylpenta-2,4-dienoate (3ab). Following the general procedure, 3ab was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a white solid (100 mg, 86%). ¹H NMR (400 MHz, CDCl₃) δ 7.48–7.38 (m, 3 H), 7.37–7.26 (m, 3 H), 6.95–6.78 (m, 2 H), 5.98 (d, *J* = 15.3 Hz, 1 H), 4.16 (t, *J* = 6.7 Hz, 2 H), 1.70–1.61 (m, 2 H), 1.41 (qd, *J* = 7.4, 15.1 Hz, 2 H), 0.95 (t, *J* = 7.3 Hz, 3 H). ¹³C NMR{¹H} (125 MHz, CDCl₃) δ 167.2, 144.6, 140.4, 136.1, 129.1, 128.9, 127.3, 126.3, 121.5, 64.4, 30.9, 19.3, 13.8. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₅H₁₉O₂ 231.1385; found 231.1382. IR (neat): *v*_{max}/ cm⁻¹ 3049, 3009, 2964, 2927, 2857, 1699, 1604, 1621, 1314, 1243, 1135, 1020.

(2*E*,4*E*)-Butyl 5-*p*-Tolylpenta-2,4-dienoate (3bb). Following the general procedure, 3bb was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a white solid (115 mg, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.42 (dd, *J* = 9.2, 15.3 Hz, 1H), 7.38–7.31 (m, *J* = 7.9 Hz, 2H), 7.20–7.11 (m, *J* = 7.9 Hz, 2H), 6.91–6.76 (m, 2H), 5.95 (d, *J* = 15.3 Hz, 1H), 4.16 (t, *J* = 6.7 Hz, 2H), 2.35 (s, 3H), 1.71–1.61 (m, 2H), 1.47–1.36 (m, 2H), 0.95 (t, *J* = 7.3 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 167.3, 144.8, 140.5, 139.3, 133.4, 129.6(2C), 127.2(2C), 125.4, 120.8, 64.3, 30.9, 21.4, 19.3, 13.8. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₁₆H₂₁O₂ 245.1542; found 245.1544. IR (neat): *v*_{max}/cm⁻¹ 2958, 1709, 1626, 1343, 1449, 1240, 1174, 1133, 1064.

(2*E*,4*E*)-Cyclohexyl 5-Phenylpenta-2,4-dienoate (3ac). Following the general procedure, 3ac was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a white solid (106 mg, 83%). ¹H NMR (500 MHz, CDCl₃) δ 7.49–7.38 (m, 3 H), 7.38–7.32 (m, 2 H), 7.32–7.26 (m, 1 H), 6.93–6.81 (m, 2 H), 5.98 (d, *J* = 15.5 Hz, 1 H), 4.90–4.79 (m, 1 H), 1.95–1.84 (m, 2 H), 1.81–1.69 (m, 2 H), 1.59–1.52 (m, 1 H), 1.52–1.34 (m, 4 H), 1.33–1.24 (m, 1 H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 166.6, 144.3, 140.2, 136.2, 129.0, 128.9, 127.2, 126.4, 122.1, 72.6, 31.8, 25.5, 23.9. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₇H₂₁O₂ 257.1542; found 257.1540. IR (neat): v_{max}/cm^{-1} 2917, 2849, 1706, 1627, 1465, 1237, 1134, 740.

(2*E*,4*E*)-Cyclohexyl 5-*p*-Tolylpenta-2,4-dienoate (3bc). Following the general procedure, 3bc was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a white solid (108 mg, 80%). ¹H NMR (500 MHz, CDCl₃) δ 7.41 (dd, *J* = 10.0, 15.2 Hz, 1 H), 7.37–7.32 (m, *J* = 8.0 Hz, 2 H), 7.18–7.13 (m, *J* = 8.0 Hz, 2 H), 6.90–6.74 (m, 2 H), 5.95 (d, *J* = 14.9 Hz, 1 H), 4.91–4.72 (m, 1 H), 2.35 (s, 3 H), 1.93–1.84 (m, 2 H), 1.75 (dd, *J* = 4.0, 9.2 Hz, 2 H), 1.63–1.52 (m, 2 H), 1.47–1.37 (m, 4 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 166.7, 144.6, 140.3, 139.3, 133.5, 129.6, 127.2, 125.5, 121.5, 72.6, 31.8, 25.5, 23.9, 21.4. HRMS (ESI-

TOF) m/z: [M + Na]⁺ calcd for C₁₈H₂₂O₂Na 293.1517; found 293.1520. IR (neat): v_{max}/cm^{-1} 2937, 1708, 1448, 1234, 1132, 1009, 846, 808.

(2*E*,4*E*)-Butyl 5-(4-Fluorophenyl)penta-2,4-dienoate (3cb). Following the general procedure, 3cb was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a white solid (83 mg, 67%). ¹H NMR (500 MHz, CDCl₃) δ 7.49–7.34 (m, 3 H), 7.03 (t, *J* = 8.6 Hz, 2 H), 6.93–6.69 (m, 2 H), 5.97 (d, *J* = 15.5 Hz, 1 H), 4.16 (t, *J* = 6.6 Hz, 2 H), 1.69–1.63 (m, 2 H), 1.46–1.37 (m, 2 H), 0.95 (t, *J* = 7.4 Hz, 3 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 167.2, 144.4, 139.0, 128.9, 128.9, 126.1, 121.5, 116.0, 115.9, 64.4, 30.9, 19.3, 13.8. HRMS (ESI-TOF) *m*/*z*: [M + Na]⁺ calcd for C₁₅H₁₇O₂FNa 271.1110; found 271.1119. IR (neat): v_{max} /cm⁻¹ 2978, 2865, 1712, 1676, 1614, 1628, 1598, 1235, 1029, 1012.

(2*E*,4*E*)-Butyl 5-(4-Bromophenyl)penta-2,4-dienoate (3db). Following the general procedure, 3db was purified by silica column chromatography (hexane/ EtOAc at a 30:1 ratio), obtained as a white solid (95 mg, 62%). ¹H NMR (400 MHz, CDCl₃) δ 7.49–7.43 (m, *J* = 7.9 Hz, 2H), 7.43–7.35 (m, 1H), 7.33–7.27 (m, *J* = 8.5 Hz, 2H), 6.89–6.76 (m, 2H), 5.99 (d, *J* = 15.3 Hz, 1H), 4.16 (t, *J* = 6.7 Hz, 2H), 1.70–1.61 (m, 2H), 1.41 (qd, *J* = 7.4, 15.0 Hz, 2H), 0.94 (t, *J* = 7.3 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 167.1, 144.1, 138.9, 135.0, 132.1 (2C), 128.6 (2C), 127.0, 123.0, 122.1, 64.5, 30.8, 19.3, 13.8. HRMS (ESI-TOF) *m*/*z*: [M + Na]⁺ calcd for C₁₅H₁₇O₂BrNa 331.0310; found 331.0315. IR (neat): ν_{max} /cm⁻¹ 3047, 3027, 3006, 2253, 1897, 1663, 1702, 1623, 1474, 1464, 1358, 1277, 1241, 1157, 1175, 1018, 1009.

(2*E*,4*E*)-Butyl 5-(4-Bromo-3-methoxyphenyl)penta-2,4-dienoate (3eb). Following the general procedure, 3eb was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a white solid (127 mg, 75%). ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 1.8 Hz, 1 H), 7.43–7.31 (m, 2 H), 6.86 (d, *J* = 8.5 Hz, 1 H), 6.80–6.67 (m, 2 H), 5.95 (d, *J* = 15.3 Hz, 1 H), 4.15 (t, *J* = 6.7 Hz, 2 H), 3.90 (s, 3 H), 1.68–1.62 (m, 2 H), 1.44–1.37 (m, 2 H), 0.96–0.92 (m, 3 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 167.2, 156.5, 144.4, 138.4, 131.7, 130.4, 127.9, 125.5, 121.2, 112.3, 112.0, 64.4, 56.4, 30.9, 19.3, 13.8. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₁₆H₁₉O₃BrNa 361.0415; found 361.0413. IR (neat): *v*_{max}/cm⁻¹ 2924, 2852,1713, 1625, 1593, 1496, 1461, 1378, 1338, 1280, 1262, 1174, 1131, 1054, 1019, 996, 871, 501, 458, 418.

(*E*)-Butyl Cinnamate (3fb). Following the general procedure, 3fb was purified by silica column chromatography (hexane/EtOAc at a 40:1 ratio), obtained as a white solid (77 mg, 80%). ¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, *J* = 16.0 Hz, 1 H), 7.49 (br. s., 2 H), 7.34 (br. s., 3 H), 6.41 (d, *J* = 16.0 Hz, 1 H), 4.17 (s, 2 H), 1.68 (s, 2 H), 1.42 (s, 2 H), 0.92 (s, 3 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 167.2, 144.6, 134.6, 130.3, 128.9, 128.1, 118.4, 64.5, 30.8, 19.3, 13.8. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₃H₁₇O₂ 205.1229; found 205.1227. IR (neat): v_{max} /cm⁻¹ 2926, 1720, 1626, 1440, 1452, 1321, 1344, 1242, 1176, 1141.

(*E*)-Cyclohexylcinnamate (3fc). Following the general procedure, 3fc was purified by silica column chromatography (hexane/EtOAc at a 40:1 ratio), obtained as a white solid (81 mg, 82%). ¹H NMR (500 MHz, CDCl₃) δ 7.66 (d, *J* = 16.0 Hz, 1 H), 7.55–7.44 (m, 2 H), 7.42–7.29 (m, 3 H), 6.43 (d, *J* = 16.0 Hz, 1 H), 4.96–4.81 (m, 1 H), 1.92 (dd, *J* = 4.6, 12.6 Hz, 2 H), 1.82–1.70 (m, 2 H), 1.62–1.45 (m, 3 H), 1.45–1.35 (m, 2 H), 1.33–1.26 (m, 1 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 166.5, 144.3, 134.7, 130.2, 128.9, 128.1, 119.0, 72.8, 31.8, 25.5, 23.9. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₁₅H₁₉O₂ 231.1385; found 231.1389. IR (neat): v_{max}/cm^{-1} 2924, 1717, 1615, 1622, 1434, 1350, 1316, 1243, 1171, 1135, 1010, 840, 806.

(*E*)-Isobutyl Cinnamate (3fd). Following the general procedure, 3fd was purified by silica column chromatography (hexane/EtOAc at a 40:1 ratio), obtained as a white solid (100 mg, 74%). ¹H NMR (500 MHz, CDCl₃) δ 7.68 (d, J = 16.0 Hz, 1 H), 7.57–7.48 (m, 2 H), 7.42–7.33 (m, 3 H), 6.45 (d, J = 16.0 Hz, 1 H), 3.99 (d, J = 6.9 Hz, 2 H), 2.01 (td, J = 6.8, 13.3 Hz, 1 H), 0.98 (d, J = 6.9 Hz, 6 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 167.2, 144.6, 134.6, 130.3, 128.9, 128.1, 118.4, 70.8, 27.9, 19.2. HRMS (ESI-TOF) m/z: [M + H]⁺

calcd for C₁₃H₁₇O₂ 205.1229; found 205.1232. IR (neat): $\nu_{max/cm}^{-1}$ 2964, 2927, 2857, 1718, 1621, 1314, 1243, 1135, 1020.

(*E*)-Benzyl Cinnamate (3fe). Following the general procedure, 3fe was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a white solid (115 mg, 68%). ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 15.9 Hz, 1 H), 7.58–7.49 (m, 2 H), 7.49–7.28 (m, 8 H), 6.50 (d, J = 15.9 Hz, 1 H), 5.26 (s, 2 H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 166.9, 145.3, 136.2, 134.4, 130.5, 129.0, 128.7, 128.4, 128.2, 118.0, 66.5. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₁₆H₁₅O₂ 239.1072; found 239.1069. IR (neat): $v_{max}/$ cm⁻¹ 2958, 1709, 1626, 1343, 1449, 1240, 1174, 1133, 1064.

(2*E*)-Methyl 3-Cyclohexenylacrylate (3ga). Following the general procedure, 3ga was purified by silica column chromatography (hexane/EtOAc at a 10:1 ratio), obtained as a colorless oil (61 mg, 81%). ¹H NMR (500 MHz, CDCl₃) δ 7.28 (d, *J* = 15.9 Hz, 1H), 6.16 (t, *J* = 3.9 Hz, 1H), 5.76 (d, *J* = 15.8 Hz, 1H), 3.73 (s, 3H), 2.20 (d, *J* = 3.4 Hz, 2H), 2.15–2.11 (m, 2H), 1.71–1.66 (m, 2H), 1.64–1.59 (m, 2H). ¹³C NMR {¹H}(100 MHz, CDCl₃) δ 168.2, 148.4, 139.0, 135.0, 114.2, 51.5, 26.5, 24.2, 22.1 (2C). HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₁₀H₁₅O₂ 167.1072; found 167.1080. IR (neat): *v*_{max}/ cm⁻¹ 2928, 2856, 1721, 1628, 1435, 1378, 1309, 1269, 1167, 1136, 1073, 982.

(2*E*)-Butyl 3-Cyclohexenylacrylate (3gb). Following the general procedure, 3gb was purified by silica column chromatography (hexane/EtOAc at a 10:1 ratio), obtained as a colorless oil (83 mg, 80%). ¹H NMR (400 MHz, CDCl₃) δ 7.26 (d, *J* = 15.9 Hz, 1 H), 6.15 (t, *J* = 4.0 Hz, 1 H), 5.75 (d, *J* = 15.3 Hz, 1 H), 4.13 (t, *J* = 6.7 Hz, 2 H), 2.23–2.09 (m, 4 H), 1.70–1.59 (m, 6 H), 1.45–1.34 (m, 2 H), 0.93 (t, *J* = 7.3 Hz, 3 H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 167.9, 148.1, 138.8, 135.0, 114.7, 64.1, 30.9, 26.5, 24.2, 22.1 (2C), 22.1, 19.3, 13.8. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₃H₂₁O₂ 209.1542; found 209.1538. IR (neat): v_{max}/cm^{-1} 2957, 2931, 2863, 1716, 1630, 1458, 1286, 1164.

(2*E*)-Cyclohexyl 3-Cyclohexenylacrylate (3gc). Following the general procedure, 3gc was purified by silica column chromatography (hexane/EtOAc at a 10:1 ratio), obtained as a colorless oil (96 mg, 82%). ¹H NMR (400 MHz, CDCl₃) δ 7.23 (s, 1 H), 6.14 (br. s., 1 H), 5.74 (d, *J* = 15.9 Hz, 1 H), 4.87–4.75 (m, 1 H), 2.24–2.08 (m, 4 H), 1.87 (dd, *J* = 4.0, 10.1 Hz, 2 H), 1.78–1.66 (m, 4 H), 1.66–1.56 (m, 3 H), 1.49–1.26 (m, 5 H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 167.2, 147.8, 138.6, 135.0, 115.3, 72.4, 31.9 (2C), 26.5, 25.5, 24.2, 23.9 (2C), 22.2 (2C). HRMS (ESI-TOF) *m*/*z*: [M + Na]⁺ calcd for C₁₅H₂₂O₂Na 257.1517; found 257.1512. IR (neat): *v*_{max}/cm⁻¹ 3025, 2934, 2859, 2661, 1712, 1629, 1450, 1435, 1350, 1318, 1301, 1286, 1167, 1039, 1018, 925.

(2*E*)-tert-Butyl 3-Cyclohexenylacrylate (3gf). Following the general procedure, 3gf was purified by silica column chromatography (hexane/EtOAc at a 10:1 ratio), obtained as a colorless oil (86 mg, 83%). ¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J* = 15.9 Hz, 1H), 6.11 (t, *J* = 4.3 Hz, 1H), 5.68 (d, *J* = 15.9 Hz, 1H), 2.21–2.15 (m, 2H), 2.11 (t, *J* = 6.1 Hz, 2H), 1.71–1.63 (m, 2H), 1.63–1.57 (m, 2H), 1.48 (s, 9H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 167.2, 147.2, 138.1, 135.0, 116.5, 80.0, 28.3 (3C), 26.5, 24.3, 22.2 (2C). HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₁₃H₂₀O₂Na 231.1361; found 231.1360. IR (neat): v_{max}/cm^{-1} 2976, 2931, 2861, 1705, 1631, 1619, 1455, 1435, 1367, 1316, 1287, 1268, 1149, 1098, 982.

(2*E*)-Methyl 3-Cyclopentenylacrylate (3ha). Following the general procedure, 3ha was purified by silica column chromatography (hexane/EtOAc at a 10:1 ratio), obtained as a colorless oil (55 mg, 80%). ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, J = 15.9 Hz, 1H), 6.16 (s, 1H), 5.72 (d, J = 15.9 Hz, 1H), 3.74 (s, 3H), 2.51–2.40 (m, 4H), 2.00–1.91 (m, 2H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 168.0, 141.5, 141.2, 140.8, 117.8, 51.6, 33.6, 30.8, 23.1. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₉H₁₃O₂ 153.0916; found 153.0916. IR (neat): v_{max}/cm^{-1} 2924, 2849, 1720, 1630, 1434, 1308, 1272, 1221, 1191, 1166, 1038, 980.

(2E,4E)-Methyl Hexa-2,4-dienoate (3ia). Following the general procedure, 3ia was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (44 mg, 70%). ¹H NMR (500 MHz, CDCl₃) & 7.27–7.20 (m, 1H), 6.22–6.08

pubs.acs.org/joc

(m, 2H), 5.76 (d, J = 15.5 Hz, 1H), 3.72 (s, 3H), 1.83 (d, J = 6.3 Hz, 3H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 167.8, 145.2, 139.5, 129.8, 118.6, 51.5, 18.7. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₇H₁₁O₂ 127.0759; found 127.0760. IR (neat): v_{max}/cm^{-1} 3483, 2955, 2925, 2853, 1724, 1650, 1437, 1309, 1271, 1172, 1200, 1029, 982, 858, 813, 633, 723, 541.

(2*E*,4*E*)-Cyclohexyl Hexa-2,4-dienoate (3ic). Following the general procedure, 3ic was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (71 mg, 73%). ¹H NMR (500 MHz, CDCl₃) δ 7.22 (dd, *J* = 10.3, 15.3 Hz, 1H), 6.28–6.07 (m, 2H), 5.76 (d, *J* = 15.3 Hz, 1H), 4.92–4.77 (m, 1H), 1.90–1.82 (m, 5H), 1.72 (dd, *J* = 5.2, 7.7 Hz, 2H), 1.62–1.35 (m, 6H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 166.9, 144.7, 139.0, 129.9, 119.8, 72.4, 31.8 (2C), 25.5, 23.9 (2C), 18.7. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₁₂H₁₉O₂ 195.1385; found 195.1389. IR (neat): ν_{max}/cm^{-1} 3025, 2934, 2661, 1712, 1629, 1450, 1435, 1350, 1318, 1286, 1167, 1039, 1018.

(*E*)-Butyl Penta-2,4-dienoate (3jb). Following the general procedure, 3jb was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (54 mg, 75%). ¹H NMR (500 MHz, CDCl₃) δ 7.29–7.22 (m, 1H), 6.50–6.40 (m, 1H), 5.90 (d, *J* = 15.5 Hz, 1H), 5.60 (d, *J* = 17.0 Hz, 1H), 5.48 (d, *J* = 10.5 Hz, 1H), 4.15 (t, *J* = 6.7 Hz, 2H), 1.67–1.61 (m, 2H), 1.40 (m, *J* = 7.5 Hz, 2H), 0.94 (t, *J* = 7.4 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 167.0, 144.6, 134.8, 125.5, 122.3, 64.4, 30.8, 19.2, 13.8. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₉H₁₅O₂ 155.1072; found 155.1075. IR (neat): v_{max}/cm^{-1} 2960, 2928, 2854, 1713, 1601, 1643, 1445, 1267, 1144.

(2*E*,4*E*)-Butyl 5-Cyclopropylpenta-2,4-dienoate (3kb). Following the general procedure, 3kb was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (76 mg, 78%). ¹H NMR (400 MHz, CDCl₃) δ 7.20 (dd, *J* = 11.6, 15.3 Hz, 1 H), 6.24 (dd, *J* = 11.0, 15.3 Hz, 1 H), 5.73 (d, *J* = 15.3 Hz, 1 H), 5.59 (dd, *J* = 9.5, 15.0 Hz, 1 H), 4.11 (t, *J* = 6.7 Hz, 2 H), 1.65–1.59 (m, 2 H), 1.53–1.44 (m, 1 H), 1.42–1.33 (m, 2 H), 0.95–0.83 (m, 5 H), 0.56–0.45 (m, 2 H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 167.6, 148.8, 144.8, 125.8, 118.0, 64.1, 30.8, 19.2, 15.0, 13.8, 8.4(2C). HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₂H₁₉O₂ 195.1385; found 195.1386. IR (neat): v_{max}/cm^{-1} 3084, 3006, 1934, 2960, 2873, 1712, 1637, 1456, 1388, 1302, 1243, 1126, 1150.

(2*E*,4*E*)-Cyclohexyl 5-Cyclopropylpenta-2,4-dienoate (3kc). Following the general procedure, 3kc was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (83 mg, 75%). ¹H NMR (500 MHz, CDCl₃) δ 7.19 (dd, *J* = 11.2, 15.2 Hz, 1 H), 6.24 (dd, *J* = 10.9, 14.9 Hz, 1 H), 5.73 (d, *J* = 15.5 Hz, 1 H), 5.59 (dd, *J* = 9.5, 15.2 Hz, 1 H), 4.85–4.75 (m, 1 H), 1.91–1.79 (m, 2 H), 1.72 (dd, *J* = 3.4, 9.2 Hz, 2 H), 1.55–1.47 (m, 2 H), 1.45–1.32 (m, 4 H), 1.30–1.24 (m, 1 H), 0.89–0.84 (m, 2 H), 0.54–0.49 (m, 2 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 167.0, 148.5, 144.6, 125.9, 118.7, 72.3, 31.8, 25.5, 23.9, 14.9, 8.4. HRMS (ESI-TOF) *m*/*z*: [M + Na]⁺ calcd for C₁₄H₂₀O₂Na 243.1361; found 243.1366. IR (neat): v_{max}/cm^{-1} 3085, 3008, 2918, 2850, 2252, 1701, 1636, 1453, 1382, 1257, 1300, 1242, 1151.

(2*E*,4*E*)-Butyl 6-Acetoxyhexa-2,4-dienoate (3lb). Following the general procedure, 3lb was purified by silica column chromatography (hexane/EtOAc at a 7:1 ratio), obtained as a colorless oil (93 mg, 82%). ¹H NMR (400 MHz, CDCl₃) δ 7.24 (dd, *J* = 11.0, 15.9 Hz, 1H), 6.37 (dd, *J* = 11.6, 15.3 Hz, 1H), 6.11 (td, *J* = 5.8, 15.3 Hz, 1H), 5.90 (d, *J* = 15.9 Hz, 1H), 4.66 (d, *J* = 6.1 Hz, 2H), 4.14 (t, *J* = 6.7 Hz, 2H), 2.08 (s, 3H), 1.70–1.61 (m, 2H), 1.39 (m, *J* = 7.5, 2H), 0.95–0.90 (m, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 170.7, 166.9, 143.1, 135.2, 130.8, 122.7, 64.5, 63.9, 30.8, 20.9, 19.2, 13.8. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₁₂H₁₉O₄ 227.1283; found 227.1285. IR (neat): v_{max}/cm^{-1} 2959, 2927, 2874, 1746, 1715, 1621, 1650, 1455, 1364, 1382, 1234, 1182, 1139, 1077, 1026, 1001.

(2E,4E)-Cyclohexyl Ethyl Hexa-2,4-dienedioate (3mc). Following the general procedure, 3mc was purified by silica column chromatography (hexane/EtOAc at a 5:1 ratio), obtained as a colorless oil (106 mg, 84%). ¹H NMR (400 MHz,CDCl₃) δ 7.36–

7.19 (m, 2H), 6.28–6.09 (m, 2H), 4.90–4.73 (m, 1H), 4.22 (q, J = 6.9 Hz, 2H), 1.86 (dd, J = 4.3, 9.2 Hz, 2H), 1.73 (dd, J = 3.7, 9.2 Hz, 2H), 1.60–1.32 (m, 6H), 1.29 (t, J = 7.3 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 166.0, 165.4, 141.0, 140.5, 131.7 (2C), 128.3, 73.3, 60.9, 31.7, 25.4, 23.8 (2C), 14.3. HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for C₁₄H₂₀O₄Na 275.1259; found 275.1252. IR (neat): v_{max}/cm^{-1} 3400, 3066, 2938, 2861, 1699, 1611, 1456, 1446, 1310, 1251, 1167, 1027, 1015, 935.

(2*E*,4*E*)-9-(Acryloyloxy)nonyl Ethyl Hexa-2,4-dienedioate (3mg). Following the general procedure, 3mg was purified by silica column chromatography (hexane/EtOAc at a 6:1 ratio), obtained as a colorless oil (124 mg, 68%). ¹H NMR (500 MHz, CDCl₃) δ 7.27 (s, 1H), 7.31 (s, 1H), 6.38 (d, *J* = 17.1 Hz, 1H), 6.24–5.97 (m, 3H), 5.79 (d, *J* = 10.4 Hz, 1H), 4.22 (q, *J* = 7.1 Hz, 2H), 4.14 (q, *J* = 7.3 Hz, 4H), 1.71–1.62 (m, 4H), 1.35–1.27 (m, 13H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 166.4, 166.1, 166.0, 140.9 (2C), 130.6, 128.7, 128.5 (2C), 65.1, 64.7, 61.0, 29.5, 29.4, 29.3, 29.2, 28.7, 26.0 (2C), 14.3. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₀H₃₁O₆ 367.2121; found 367.2128. IR (neat): $v_{max/cm}^{-1}$ 3070, 2928, 2855, 1721, 1703, 1613, 1473, 1313, 1295, 1260, 1240, 1021.

(2*E*,4*E*)-5-*p*-Tolylpenta-2,4-dienenitrile (5ba). Following the general procedure, 5ba was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a white solid (70 mg, 83%). ¹H NMR (400 MHz, CDCl₃) δ 7.34 (d, *J* = 7.9 Hz, 2H), 7.18–7.09 (m, 3H), 6.87–6.76 (m, 2H), 5.39 (d, *J* = 15.9 Hz, 1H), 2.35 (s, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 150.6, 141.5, 140.1, 132.6, 129.8 (2C), 127.5 (2C), 124.6, 118.6, 97.6, 21.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₂H₁₂N 170.0970; found 170.0971. IR (neat): *v*_{max}/cm⁻¹ 3028, 3049,2924, 2856,2254, 2209, 1732, 1605, 1623, 1593, 1454, 1310, 1286, 1153, 968, 995, 980.

(2*E*,4*E*)-5-(4-Bromophenyl)penta-2,4-dienenitrile (5ca). Following the general procedure, 5ca was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a white solid (80 mg, 68%). ¹H NMR (500 MHz, CDCl₃) δ 7.49 (d, *J* = 8.6 Hz, 2H), 7.31 (d, *J* = 8.6 Hz, 2H), 7.12 (ddd, *J* = 2.6, 7.3, 16 Hz, 1H), 6.85–6.74 (m, 2H), 5.45 (d, *J* = 16.0 Hz, 1H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 150.0, 140.0, 134.3, 132.2 (2C), 128.8 (2C), 126.1, 123.9, 118.2, 99.1. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₁H₉NBr 233.9918; found 233.9925. IR (neat): v_{max} /cm⁻¹ 3051, 3019, 2923, 2853, 2253, 2211, 1911, 1737, 1620, 1597, 1579, 1486, 1467, 1402, 1274, 1150, 1099, 1007, 1071, 983, 948.

(2*E*,4*E*)-5-(4-Fluorophenyl)penta-2,4-dienenitrile (5da). Following the general procedure, 5da was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a white solid (86 mg, 60%). ¹H NMR (500 MHz, CDCl₃) δ 7.43 (dd, *J* = 5.4, 8.4 Hz, 2H), 7.13 (dd, *J* = 10.7, 15.9 Hz, 1H), 7.06 (t, *J* = 8.6 Hz, 2H), 6.84 (d, *J* = 15.6 Hz, 1H), 6.73 (dd, *J* = 10.8, 15.5 Hz, 1H), 5.43 (d, *J* = 15.9 Hz, 1H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 164.5, 162.6 (d, ¹J_{CF} = 262.5 Hz), 150.2, 140.1, 131.6, 129.2 (2C, d, ³J_{CF} = 8.75 Hz) 125.3, 118.3, 116.3, 116.1 (2C, d, ²J_{CF} = 21.2 Hz), 98.4. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₁H₉NF 174.0719; found 174.0720. IR (neat): v_{max}/cm^{-1} 2911, 2883, 2212, 1726, 1671, 1616, 1402,1288, 1219, 1151, 1172, 1047, 983.

Cinnamonitrile (5fa). Following the general procedure, **Sfa** was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a white solid (77 mg, 85%). ¹H NMR (500 MHz, CDCl₃) δ 7.47–7.35 (m, 6 H), 5.87 (d, *J* = 17.2 Hz, 1 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 150.7, 133.6, 131.3, 129.2, 127.4, 118.2, 96.4. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₉H₁₀N 132.0813; found 132.0818. IR(neat): *v*_{max}/cm⁻¹ 2929, 2856, 1628, 1439, 1450, 1324, 1342, 1240, 1172, 1137, 1031.

(2*E*)-3-Cyclohexenylacrylonitrile (5ga). Following the general procedure, 5ga was purified by silica column chromatography (hexane/EtOAc at a 30:1 ratio), obtained as a colorless oil (62 mg, 78%). ¹H NMR (500 MHz, CDCl₃) δ 6.98 (d, *J* = 16.4 Hz, 1 H), 6.14 (t, *J* = 4.2 Hz, 1 H), 5.17 (d, *J* = 16.3 Hz, 1 H), 2.24–2.19 (m, 2 H), 2.09–2.04 (m, 2 H), 1.71–1.66 (m, 2 H), 1.61 (td, *J* = 2.6, 8.4 Hz, 2 H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 153.8, 140.0, 134.7, 92.4, 26.4, 23.5, 21.8, 21.8. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for

 $C_9H_{12}N$ 134.0970; found 134.0970. IR (neat): ν_{max}/cm^{-1} 3058, 2927, 2857, 2215, 1738, 1626, 1598, 1448, 1434, 1378, 965.

(2*E*,4*E*)-Ethyl 5-Cyanopenta-2,4-dienoate (5ma). Following the general procedure, 5ma was purified by silica column chromatography (hexane/EtOAc at a 10:1 ratio), obtained as a colorless oil (66 mg, 75%). ¹H NMR (500 MHz,CDCl₃) δ 7.24 (dd, *J* = 11.5, 15.5 Hz, 1H), 7.07 (dd, *J* = 11.2, 15.8 Hz, 1H), 6.19 (d, *J* = 14.3 Hz, 1H), 5.70 (d, *J* = 15.5 Hz, 1H), 4.24 (q, *J* = 6.9 Hz, 2H), 1.30 (t, *J* = 7.2 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 165.4, 147.1, 139.5, 129.6, 116.9, 106.1, 61.3, 14.3. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₈H₁₀NO₂ 152.0712; found 152.0715. IR (neat): v_{max}/cm^{-1} 3404, 3028, 3054, 2987, 2960, 2926, 2855, 2255, 2217, 1710, 1670, 1636, 1263, 1183, 1001, 910.

(1*E*)-1-Cyclohexenylpent-1-en-3-one (5gb). Following the general procedure, 5gb was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (60 mg, 73%). ¹H NMR (400 MHz, CDCl₃) δ 7.14 (d, *J* = 15.9 Hz, 1H), 6.19 (t, *J* = 4.3 Hz, 1H), 6.06 (d, *J* = 16.5 Hz, 1H), 2.58 (q, *J* = 7.3 Hz, 2H), 2.24–2.17 (m, 2H), 2.16–2.11 (m, 2H), 1.72–1.65 (m, 2H), 1.64–1.59 (m, 2H), 1.10 (t, *J* = 7.3 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 201.7, 146.0, 139.7, 135.3, 123.1, 33.7, 26.7, 24.3, 22.1(2C), 8.5. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₁₁H₁₆ONa 187.1099; found 187.1096. IR (neat): v_{max} /cm⁻¹ 2931, 2860, 1688, 1664, 1625, 1598, 1434, 1458, 1375, 1278, 1194, 1120, 1049, 1035.

(1*E*)-1-Cyclopentenylpent-1-en-3-one (5hb). Following the general procedure, 5hb was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (56 mg, 74%). ¹H NMR (500 MHz, CDCl₃) δ 7.37 (d, *J* = 16.0 Hz, 1 H), 6.21 (br. s., 1 H), 6.01 (d, *J* = 16.0 Hz, 1 H), 2.59 (q, *J* = 7.4 Hz, 2 H), 2.51–2.41 (m, 4 H), 2.02–1.88 (m, 2 H), 1.11 (t, *J* = 7.4 Hz, 3 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 201.8, 141.9, 141.5, 138.6, 126.6, 33.7, 33.6, 30.9, 23.2, 8.4. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₀H₁₅O 151.1123; found 151.1122. IR (neat): v_{max}/cm^{-1} 3372, 3039, 2924, 2954, 2851, 1690, 1668, 1612, 1590, 1460, 1411, 1375, 1189, 1119, 1037.

(4*E*,6*E*)-7-Cyclopropylhepta-4,6-dien-3-one (5kb). Following the general procedure, Skb was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (56 mg, 75%). ¹H NMR (400 MHz, CDCl₃) δ 7.10 (dd, *J* = 11.3, 15.4 Hz, 1H), 6.25 (dd, *J* = 10.9, 15.0 Hz, 1H), 6.04 (d, *J* = 15.4 Hz, 1H), 5.64 (dd, *J* = 9.5, 15.0 Hz, 1H), 2.54 (q, *J* = 7.4 Hz, 2H), 1.54–1.46 (m, 1H), 1.09 (t, *J* = 7.2 Hz, 3H), 0.91–0.86 (m, 2H), 0.56–0.51 (m, 2H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 201.5, 149.8, 142.7, 126.6, 126.4, 33.7, 15.2, 8.6, 8.4(2C). HRMS (ESI-TOF) *m*/*z*: [M + Li]⁺ calcd for C₁₀H₁₄OLi 157.1205; found 157.1208. IR (neat): $ν_{max}$ /cm⁻¹ 3085, 3007, 2975, 2927, 2855, 1897, 1715, 1688, 1662, 1632, 1595, 1455, 1377, 1281, 1201, 1033, 1049, 997, 950, 861.

1-((1*E*,3*E*)-Nona-1,3-dienylsulfonyl)benzene (5nc). Following the general procedure, Snc was purified by silica column chromatography (hexane/EtOAc at a 3:1 ratio), obtained as a white solid (92 mg, 70%). ¹H NMR (500 MHz, CDCl₃) δ 7.88 (dd, J = 0.9, 8.2 Hz, 2H), 7.62–7.56 (m, 1H), 7.56–7.47 (m, 2H), 7.24 (dd, J = 10.9, 14.7 Hz, 1H), 6.29–6.20 (m, 2H), 6.09 (dd, J = 10.9, 15.2 Hz, 1H), 2.16 (q, J = 7.1 Hz, 2H), 1.41 (q, J = 7.3 Hz, 2H), 1.30–1.25 (m, 4H), 0.87 (t, J = 6.9 Hz, 3H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 148.1, 143.1, 141.2, 133.2, 129.3 (2C), 127.6 (2C), 127.5, 126.1, 33.1, 31.4, 28.2, 22.5, 14.1. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₁₅H₂₁SO₂ 265.1262; found 265.1260. IR (neat): $ν_{max}/cm^{-1}$ 3404, 3028, 3054, 2987, 2960, 2926, 2855, 2255, 2217, 1710, 1670, 1636, 1263, 1183, 1001, 910.

1-((1*E***)-2-Cyclopentenylvinylsulfonyl)benzene (5hc).** Following the general procedure, **5hc** was purified by silica column chromatography (hexane/EtOAc at a 3:1 ratio), obtained as a white solid (89 mg, 76%). ¹H NMR (400 MHz, CDCl₃) δ 7.91–7.85 (m, 2H), 7.62–7.56 (m, 1H), 7.56–7.45 (m, 3H), 6.33–6.26 (m, 1H), 6.16 (dd, *J* = 0.8, 15.0 Hz, 1H), 2.53–2.44 (m, 2H), 2.38–2.32 (m, 2H), 1.94 (m, 2H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 143.8, 141.2, 139.5, 138.9, 133.2, 129.3 (2C), 127.6 (2C), 126.9, 33.8, 30.9,

23.1. HRMS (ESI-TOF) m/z: $[M + H]^+$ calcd for $C_{13}H_{15}SO_2$ 235.0793; found 235.0787. IR (neat): v_{max}/cm^{-1} 3028, 3054, 2987, 2960, 2926, 2217, 1710, 1670, 1636, 1263.

(*E*)-Cinnamamide (5fd). Following the general procedure, 5fd was purified by silica column chromatography (hexane/EtOAc at a 1:4 ratio), obtained as a white solid (77 mg, 81%). ¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, *J* = 15.6 Hz, 1 H), 7.57–7.45 (m, 2 H), 7.38 (br. s., 3 H), 6.45 (d, *J* = 15.8 Hz, 1 H), 5.58 (br. s., 2 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 166.7, 141.7, 133.6, 129.1, 127.9, 127.0, 118.5. HRMS (ESI-TOF) *m*/*z*: [M + Na]⁺ calcd for C₉H₉NONa 170.0582; found 170.0586. IR (neat): *v*_{max}/cm⁻¹ 2926, 1665, 1594, 1439, 1450, 1321, 1344, 1241, 1173, 1139, 1035.

(2*E*)-3-Cyclopentenylacrylamide (5hd). Following the general procedure, Shd was purified by silica column chromatography (hexane/EtOAc at a 1:4 ratio), obtained as a sticky solid (54 mg, 79%). ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, *J* = 15.9 Hz, 1H), 6.13 (s, 1H), 5.73 (d, *J* = 15.3 Hz, 1H), 5.58 (br. s., 2H), 2.51–2.36 (m, 4H), 1.96 (m, *J* = 7.6 Hz, 2H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 168.7, 141.2, 140.1, 138.8, 119.5, 33.5, 31.0, 23.2. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₈H₁₂ON 138.0919; found 138.0914. IR (neat): ν_{max}/cm^{-1} 3355, 3169, 2954, 2852, 2923, 1662, 1592, 1397, 1462, 1439, 1243, 1103, 1037.

(2*E*,4*E*)-Methyl 3-Methyl-5-phenylpenta-2,4-dienoate (5ae). Following the general procedure, 5ae was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a white solid (66 mg, 65%). ¹H NMR (400 MHz, CDCl₃) δ 7.48–7.41 (m, 2H), 7.37–7.31 (m, 2H), 7.31–7.25 (m, 1H), 6.94 (d, *J* = 16.5 Hz, 1H), 6.80 (d, *J* = 15.9 Hz, 1H), 5.90 (s, 1H), 3.72 (s, 3H), 2.40 (s, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 167.5, 152.5, 136.4, 134.3, 131.9, 128.9 (2C), 128.7, 127.1 (2C), 119.4, 51.2, 13.8. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₃H₁₅O₂ 203.1072; found 203.1075. IR (neat): v_{max}/cm^{-1} 1712, 1609, 1433, 1357,1238, 1154, 960, 690.

(E)-7-Phenylhept-6-en-3-one (6ab). Following the general procedure, 6ab was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a white solid (68 mg, 70%). ¹H NMR (400 MHz, CDCl₃) δ 7.33–7.25 (m, 4H), 7.22–7.15 (m, 1H), 6.39 (d, J = 15.9 Hz, 1H), 6.18 (td, J = 6.7, 15.9 Hz, 1H), 2.61–2.54 (m, 2H), 2.52–2.39 (m, 4H), 1.06 (t, J = 7.3 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 210.8, 137.5, 130.8, 129.1, 128.6 (2C), 127.2, 126.1 (2C), 41.9, 36.2, 27.3, 7.9. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₁₃H₁₇O 189.1279; found 189.1282. IR (neat): v_{max}/cm^{-1} 3059, 3025, 2974, 2934, 2852, 1714, 1597, 1448, 1260, 1114, 1027.

(*E*)-7-*p*-Tolylhept-6-en-3-one (6bb). Following the general procedure, 6bb was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a white solid (76 mg, 75%). ¹H NMR (400 MHz, CDCl₃) δ 7.23–7.18 (m, *J* = 8.5 Hz, 2H), 7.11–7.05 (m, *J* = 7.9 Hz, 2H), 6.36 (d, *J* = 15.9 Hz, 1H), 6.13 (td, *J* = 6.7, 15.9 Hz, 1H), 2.56 (d, *J* = 7.3 Hz, 2H), 2.50–2.40 (m, 4H), 2.31 (s, 3H), 1.05 (t, *J* = 7.3 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 210.9, 136.9, 134.7, 130.6, 129.3 (2C), 128.0, 126.0 (2C), 42.0, 36.1, 27.3, 21.2, 7.9. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₁₄H₁₉O 203.1436; found 203.1432. IR (neat): *v*_{max}/cm⁻¹ 3413, 3022, 2922, 2853, 1899, 1714, 1612, 1581, 1512, 1458, 1411, 1375, 1306, 1260, 1208, 1181, 1112, 1067, 1019.

4-Phenylbutan-2-one (6ff). Following the general procedure, **6ff** was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (60 mg, 65%). ¹H NMR (500 MHz,CDCl₃) δ 7.32–7.22 (m, 2 H), 7.22–7.11 (m, 3 H), 2.89 (t, *J* = 7.7 Hz, 2 H), 2.76 (t, *J* = 7.7 Hz, 2 H), 2.14 (s, 3 H). ¹³C NMR {¹H} (125 MHz, CDCl₃) δ 207.0, 140.1, 127.6, 127.4, 125.2, 44.3, 29.2, 28.8. HRMS (ESI-TOF) *m*/*z*: $[M + H]^+$ calcd for C₁₀H₁₃O 149.0966; found 149.0969. IR (neat): *v*_{max/}cm⁻¹ 2931, 2860, 1720, 1664, 1625, 1588, 1458, 1375, 1278, 1194, 1120, 1049, 1035.

1-Cyclopentenylpentan-3-one (6hb). Following the general procedure, **6hb** was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (50 mg, 65%). ¹H NMR (500 MHz, CDCl₃) δ 5.41–5.21 (m, 1H), 2.58–2.53 (m, 2H), 2.46–2.40 (m, 2H), 2.33 (t, *J* = 8.0 Hz, 2H), 2.27 (ddd, *J* = 2.3, 4.7, 9.6 Hz, 2H), 2.22 (t, *J* = 8.6 Hz, 2H), 1.87–1.80 (m, 2H),

pubs.acs.org/joc

1.05 (t, J = 7.4 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 211.4, 143.4, 123.7, 40.8, 35.9, 35.3, 32.5, 25.4, 23.4, 7.9. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₁₀H₁₇O 153.1279; found 153.1280. IR (neat): $v_{\text{max}}/\text{cm}^{-1}$ 3045, 2925, 2850, 1717, 1651, 1614, 1460, 1413, 1376, 1111, 978.

(E)-Undec-5-en-2-one (6nf). Following the general procedure, **6nf** was purified by silica column chromatography (hexane/EtOAc at a 20:1 ratio), obtained as a colorless oil (50 mg, 60%). ¹H NMR (400 MHz, CDCl₃) δ 5.49–5.27 (m, 2H), 2.49–2.42 (m, 2H), 2.23 (q, *J* = 6.7 Hz, 2H), 2.11 (s, 3H), 1.97–1.87 (m, 2H), 1.35–1.25 (m, 6H), 0.85 (t, *J* = 6.7 Hz, 3H). ¹³C NMR {¹H} (100 MHz, CDCl₃) δ 208.6, 131.7, 128.2, 43.7, 32.5, 31.4, 30.0, 29.2, 26.9, 22.6, 14.1. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₁₁H₂₁O 169.1592; found 169.1593. IR (neat): *v*_{max}/cm⁻¹ 2957, 2925, 2855, 1718, 1440, 1359, 1160, 969.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.0c02823.

Copies of 1H and 13C spectra for all products and table of results from kinetics NMR experiments (PDF)

AUTHOR INFORMATION

Corresponding Author

Dattatraya H. Dethe – Department of Chemistry, Indian Institute of Technology Kanpur, Kanpur 208016, India; orcid.org/0000-0003-2734-210X; Email: ddethe@ iitk.ac.in

Authors

- Nagabhushana C. Beeralingappa Department of Chemistry, Indian Institute of Technology Kanpur, Kanpur 208016, India
- Amar Uike Department of Chemistry, Indian Institute of Technology Kanpur, Kanpur 208016, India

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.joc.0c02823

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

N.C.B. and A.U. thank UGC, New Delhi, for the award of a research fellowship. Financial support from SERB Project No. EMR/2017/001455 is gratefully acknowledged.

REFERENCES

(1) (a) Mizoroki, T.; Mori, K.; Ozaki, A. Arylation of Olefin with Aryl Iodide Catalyzed by Palladium. *Bull. Chem. Soc. Jpn.* **1971**, *44*, 581. (b) Heck, R.; Nolley, J. P. Palladium-catalyzed vinylic hydrogen substitution reactions with aryl, benzyl, and styryl halides. *J. Org. Chem.* **1972**, *37*, 2320.

(2) For reviews of the Heck reaction, see (a) Diederich, F.; de Meijere, A. Metal-Catalyzed Cross-Coupling Reactions; Wiley: New York, 1998; Chapter 3. (b) Beletskaya, I. P.; Cheprakov, A. V. Heck Reaction as a Sharpening Stone of Palladium Catalysis. Chem. Rev. 2000, 100, 3009. (c) Heck, R. F. Comprehensive Organic Synthesis; Trost, B. M., Ed.; Pergamon: New York, 1991; Vol. 4. Chapter 4.3. (d) Heck, R. F. Palladium-Catalyzed Vinylation of Organic Halides. Org. React. 1982, 27, 345. (e) Crisp, G. T. Variations on a theme-recent developments on the mechanism of the Heck reaction and their implications for synthesis. Chem. Soc. Rev. 1998, 27, 427. (f) de Meijere, A.; Meyer, F. E. Fine Feathers Make Fine Birds: The Heck Reaction in Modern Garb. Angew. Chem. Int. Ed. Engl. 1995, 33, 2379. (g) Jeffery, T.; Liebeskind, L. S. Advances in Metal-Organic Chemistry;

pubs.acs.org/joc

JAI: London, 1996; Vol. 5, p 153. (h) Cabri, W.; Candiani, I. Recent Developments and New Perspectives in the Heck Reaction. *Acc. Chem. Res.* **1995**, *28*, 2.

(3) For example, see the following (a) Danishefsky, S. J.; Masters, J. J.; Young, W. B.; Link, J. T.; Snyder, L. B.; Magee, T. V.; Jung, D. K.; Isaacs, R. C. A.; Bornmann, W. G.; Alaimo, C. A.; Coburn, C. A.; Di Grandi, M. J. Total Synthesis of Baccatin III and Taxol. J. Am. Chem. Soc. **1996**, 118, 2843. (b) Overman, L. E.; Ricca, D. J.; Tran, V. D. First total synthesis of scopadulcic acid B. J. Am. Chem. Soc. **1993**, 115, 2042.

(4) (a) Link, J. T.; Overman, L. E.; Diederich, F.; Stang, P. J. Metal-Catalyzed Cross-Coupling Reactions; Wiley-VCH: New York, 1998; Chapter 6. (b) Nicolaou, K. C.; Sorensen, E. J. Classics in Total Synthesis; VCH: New York, 1996; Chapter 31. These authors refer to the Heck reaction as "one of the true "power tools" of contemporary organic synthesis"

(5) For example, see (a) Hedrick, J. L.; Labadie, J. W. ACS Symposium Series 624; American Chemical Society: DC Washington, 1996; Chapters 1, 2, and 4. (b) Devries, R. A.; Vosejpka, P. C.; Ash, M. L.; Herkes, F. E. Catalysis of Organic Reactions; Marcel Dekker: New York, 1998; Chapter 37. (c) Tietze, L. F.; Kettschau, G.; Heuschert, U.; Nordmann, G. Highly Efficient Synthesis of Linear Pyrrole Oligomers by Two fold Heck Reactions. Chemistry 2001, 7, 368.

(6) For some recent examples, see (a) Häberli, A.; Leumann, C. Synthesis of Pyrrolidine C-Nucleosides via Heck Reaction. Org. Lett. **2001**, *3*, 489. (b) Burke, T. R., Jr.; Liu, D.-G.; Gao, Y. Use of a Heck reaction for the synthesis of a new alpha-azido phosphotyrosyl mimetic suitably protected for peptide synthesis. J. Org. Chem. **2000**, *65*, 6288.

(7) (a) Deagostino, A.; Prandi, C.; Zavattaro, C.; Venturello, P. Functionalized 1-Alkoxy-1,3-dienes: Their Preparation and Applications in Synthetic Organic Chemistry. Eur. J. Org. Chem. 2006, 2006, 2463. (b) Nicolaou, K. C.; Snyder, S. A.; Montagnon, T.; Vassilikogiannakis, G. The Diels Alder Reaction in Total Synthesis. Angew. Chem., Int. Ed. 2002, 41, 1668. (c) Fürstner, A.; Nevado, C.; Waser, M.; Tremblay, M.; Chevrier, C.; Teply, F.; Aissa, C.; Moulin, E.; Muller, O. Total Synthesis of Iejimalide A-D and Assessment of the Remarkable Actin-Depolymerizing Capacity of These Polyene Macrolides. J. Am. Chem. Soc. 2007, 129, 9150. (d) McCammant, M. S.; Liao, L.; Sigman, M. S. Palladium-Catalyzed 1,4-Difunctionalization of Butadiene To Form Skipped Polyenes. J. Am. Chem. Soc. 2013, 135, 4167. (e) Kotha, S.; Chavan, A. S.; Goyal, D. Diversity-Oriented Approaches to Polycyclics and Bioinspired Molecules via the Diels-Alder Strategy: Green Chemistry, Synthetic Economy, and Beyond. ACS Comb. Sci. 2015, 17, 253. (f) Saini, V.; O'Dair, M.; Sigman, M. S. Synthesis of Highly Functionalized Tri- and Tetra- substituted Alkenes via Pd-Catalyzed 1,2-Hydrovinylation of Terminal 1,3-Dienes. J. Am. Chem. Soc. 2015, 137, 608. (g) Adamson, N. J.; Hull, E.; Malcolmson, S. J. Enantioselective Intermolecular Addition of Aliphatic Amines to Acyclic Dienes with a Pd-PHOX Catalyst. J. Am. Chem. Soc. 2017, 139, 7180. (h) Christian, A. H.; Niemeyer, Z. L.; Sigman, M. S.; Toste, F. D. Uncovering Subtle Ligand Effects of Phosphines Using Gold(I) Catalysis. ACS Catal. 2017, 7, 3973.

(8) Timsina, Y. N.; Biswas, S.; RajanBabu, T. V. Chemoselective Reactions of (E)-1,3-Dienes: Cobalt-Mediated Isomerization to (Z)-1,3-Dienes and Reactions with Ethylene. *J. Am. Chem. Soc.* **2014**, *136*, 6215.

(9) (a) Hu, T.-J.; Zhao, M.-Y.; Li, Q.; Feng, C.-G.; Lin, G.-Q. Highly Stereoselective Synthesis of 1,3-Dienes through an Aryl to Vinyl 1,4-Palladium Migration/Heck Sequence. *Angew. Chem., Int. Ed.* **2018**, *57*, 5871. (b) De Paolis, M.; Chataigner, I.; Maddaluno, J. Recent Advances in Stereoselective Synthesis of 1,3-Dienes. In *Topics in Current Chemistry*, 2012; Vol. 327, p 87.

(10) (a) Gurtler, C.; Buchwald, S. L. A Phosphane-Free Catalyst System for the Heck Arylation of Disubstituted Alkenes: Application to the Synthesis of Trisubstituted Olefins. *Chem. - Eur. J.* **1999**, *5*, 3107. (b) Beletskaya, I. P.; Cheprakov, A. V. The Heck Reaction as a Sharpening Stone of Palladium Catalysis. *Chem. Rev.* **2000**, *100*, 3009. (c) Whitcombe, N. J.; Hii, K. K.; Gibson, S. E. Advances in the Heck chemistry of aryl bromides and chlorides. *Tetrahedron* 2001, *57*, 7449.
(d) Kondolff, I.; Doucet, H.; Santelli, M. Tetraphosphine/palladium-catalyzed Heck reactions of aryl halides with disubstituted alkenes. *Tetrahedron Lett.* 2003, *44*, 8487.

(11) For reviews of the Heck reaction see (a) Dounay, A. B.; Overman, L. E. Advances in the Heck chemistry of aryl bromides and chlorides. *Chem. Rev.* **2003**, *103*, 2945. (b) Crisp, G. T. Variations on a theme-recent developments on the mechanism of the Heck reaction and their implications for synthesis. *Chem. Soc. Rev.* **1998**, *27*, 427. (c) Heck, R. F.; Trost, B. M. *Comprehensive Organic Synthesis*; Pergamon: New York, 1991; Chapter 4.3, Vol. 4. (d) Cabri, W.; Candiani, I. Recent Developments and New Perspectives in the Heck Reaction. *Acc. Chem. Res.* **1995**, *28*, 2.

(12) For examples of oxidative Heck reactions see (a) Werner, E. W.; Sigman, M. S. Operationally Simple and Highly (E)-Styrenyl-Selective Heck Reactions of Electronically Nonbiased Olefins. J. Am. Chem. Soc. 2011, 133, 9692. (b) Jung, Y. C.; Mishra, R. K.; Yoon, C. H.; Jung, K. W. Oxygen-Promoted Pd(II) Catalysis for the Coupling of Organoboron Compounds and Olefins. Org. Lett. 2003, 5, 2231. (c) Parrish, J. P.; Jung, Y. C.; Shin, S. I.; Jung, K. W. Mild and Efficient Aryl-Alkenyl Coupling via Pd(II) Catalysis in the Presence of Oxygen or Cu(II) Oxidants. J. Org. Chem. 2002, 67, 7127. (d) Andappan, M. M. S.; Nilsson, P.; Schenck, H.; von Larhed, M. Dioxygen-Promoted Regioselective Oxidative Heck Arylations of Electron-Rich Olefins with Arylboronic Acids. J. Org. Chem. 2004, 69, 5212. (e) Lindh, J.; Enquist, P.-A.; Pilotti, A.; Nilsson, P.; Larhed, M. Efficient Palladium(II) Catalysis under Air. Base-Free Oxidative Heck Reactions at Room Temperature or with Microwave Heating. J. Org. Chem. 2007, 72, 7957. (f) Cho, C. S.; Uemura, S. Palladium-catalyzed cross-coupling of aryl and alkenyl boronic acids with alkenes via oxidative addition of a carbon- boron bond to palladium (0). J. Organomet. Chem. 1994, 465, 85.

(13) For examples of classical Heck vinylations see (a) Littke, A. F.; Fu, G. C. A Versatile Catalyst for Heck Reactions of Aryl Chlorides and Aryl Bromides under Mild Conditions. J. Am. Chem. Soc. 2001, 123, 6989. (b) Lemhadri, M.; Battace, A.; Berthiol, F.; Zair, T.; Doucet, H.; Santelli, M. Palladium-Tetraphosphine Complex Catalysed Heck Reaction of Vinyl Bromides with Alkenes: A Powerful Access to Conjugated Dienes. Synthesis 2008, 1142. (c) McConville, M.; Saidi, O.; Blacker, J.; Xiao, J. Regioselective Heck Vinylation of Electron-Rich Olefins with Vinyl Halides: Is the Neutral Pathway in Operation? J. Org. Chem. 2009, 74, 2692. (d) Battace, A.; Zair, T.; Doucet, H.; Santelli, M. Heck Vinylations Using Vinyl Sulfide, Vinyl Sulfoxide, Vinyl Sulfone, or Vinyl Sulfonate Derivatives and Aryl Bromides Catalyzed by a Palladium Complex Derived from a Tetraphosphine. Synthesis 2006, 3495. (e) Fayol, A.; Fang, Y.-Q.; Lautens, M. Synthesis of 2-Vinylic Indoles and Derivatives via a Pd-Catalyzed Tandem Coupling Reaction. Org. Lett. 2006, 8, 4203. (f) Liao, L.; Jana, R.; Urkalan, K. B.; Sigman, M. S. A Palladium-Catalyzed Three-Component Cross-Coupling of Conjugated Dienes or Terminal Alkenes with Vinyl Triflates and Boronic Acids. J. Am. Chem. Soc. 2011, 133, 5784.

(14) (a) Knowles, J. P.; O'Conner, V. E.; Whiting, A. Studies towards the synthesis of the northern polyene of viridenomycin and synthesis of Z-double bond analogues. *Org. Biomol. Chem.* **2011**, *9*, 1876. (b) Kim, H. J.; Pongdee, R.; Wu, Q.; Hong, L.; Liu, H. The biosynthesis of spinosyn in Saccharopolyspora spinosa: synthesis of the cross-bridging precursor and identification of the function of SpnJ. *J. Am. Chem. Soc.* **2007**, *129*, 14582. (c) Grushin, V. V. Hydrido Complexes of Palladium. *Chem. Rev.* **1996**, *96*, 2011. (d) Hills, I. D.; Fu, G. C. Elucidating Reactivity Differences in Palladium-Catalyzed Coupling Processes: The Chemistry of Palladium Hydrides. *J. Am. Chem. Soc.* **2004**, *126*, 13178.

(15) Yoo, K. S.; Yoon, C. H.; Jung, K. W. Oxidative Palladium(II) Catalysis: A Highly Efficient and Chemoselective Cross-Coupling Method for Carbon-Carbon Bond Formation under Base-Free and Nitrogenous-Ligand Conditions. J. Am. Chem. Soc. **2006**, 128, 16384.

(16) (a) Singh, S.; Bruffaerts, J.; Vasseu, A.; Marek, I. A unique Pdcatalysed Heck arylation as a remote trigger for cyclopropane selective ring-opening. *Nat. Commun.* **2017**, *8*, No. 14200. (b) Baeckvall, J.-E.; Bjorkman, E. E.; Pettersson, L.; Siegbahn, P.; Strichlbc, A. A Theoretical Study of the Cyclopropane Ring Opening by Palladium. *J. Am. Chem. Soc.* **1985**, *107*, 7408. (c) Tait, K.; Alrifai, O.; Boutin, R.; Haner, J.; Tam, W. Palladium-catalyzed ring-opening reactions of cyclopropanated 7-oxabenzonorbornadiene with alcohols. *Beilstein J. Org. Chem.* **2016**, *12*, 2189.

(17) (a) Rappoport, Z. The Chemistry of Dienes and Polyenes; Wiley: New York, 1997. (b) Yet, L. Chemistry and Biology of Salicylihalamide A and Related Compounds. *Chem. Rev.* **2003**, *103*, 4283. (c) Matsumoto, A.; Odani, T.; Sada, K.; Miyata, M.; Tashiro, K. Intercalation of alkylamines into an organic polymer crystal. *Nature* **2000**, *405*, 328.

(18) Hu, X.-H.; Zhang, J.; Yang, X.-F.; Xu, Y.-H.; Loh, T.-P. Stereoand Chemoselective Cross-Coupling between Two Electron-Deficient Acrylates: An Efficient Route to (Z,E)-Muconate Derivatives. J. Am. Chem. Soc. **2015**, 137, 3169.

(19) (a) Beletskaya, I. P.; Cheprakov, A. V. The Heck Reaction as a Sharpening Stone of Palladium Catalysis. *Chem. Rev.* **2000**, *100*, 3009. (b) Crisp, G. T.; Glink, P. T. Elaboration of the side chain of α -amino acids containing a vinyl iodide by palladium-catalysed coupling. *Tetrahedron* **1994**, *50*, 2623. (c) Kim, J.-I.; Patel, B. A.; Heck, R. F. Palladium catalyzed synthesis of 2,4-dienoic acid derivatives from vinylic halides. J. Org. Chem. **1981**, *46*, 1067.

(20) (a) Manikandan, R.; Jeganmohan, M. Recent Advances in the Ruthenium(ii)-Catalyzed Chelation-Assisted C-H Olefination of Substituted Aromatics, Alkenes and Heteroaromatics with Alkenes via the Deprotonation Pathway. *Chem. Commun.* **2017**, *53*, 8931. (b) Dethe, D. H.; Nagabhushana, C. B. Ruthenium-Catalyzed Direct Dehydrogenative Cross-Coupling of Allyl Alcohols and Acrylates: Application to Total Synthesis of Hydroxy β -Sanshool, ZP-Amide I, and Chondrillin. *Org. Lett.* **2020**, *22*, 1618. (c) Laru, S.; Bhattacharjee, S.; Singsardar, M.; Samanta, S.; Hajra, A. Ru(II)-Catalyzed Switchable C–H Alkylation and Spirocyclization of 2-Arylquinoxalines with Maleimides via ortho-C–H Activation. J. Org. Chem.. DOI: 10.1021/acs.joc.0c02745.